Across TCGA pan-cancer cohorts, NUP42 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NUP42 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher NUP42 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUP42 expression acts as an unfavorable survival marker.
PRAD and SKCM are the cancer types where NUP42 Mutation most reproducibly stratifies survival.